Årsagen kan fx være ambrisentan eller eksisterende hjerteinsufficiens, og det vurderes om der kræves specifik behandling eller seponering af ambrisentanbehandlingen.
If clinically significant fluid retention develops during therapy with ambrisentan, with or without associated weight gain, further evaluation should be undertaken to determine the cause, such as ambrisentan or underlying heart failure, and the possible need for specific treatment or discontinuation of ambrisentan therapy.